PARIS, Oct 27 (Reuters) - French biotechnology company NicOx (NCOX.PA: Quote, Profile, Research) said on Thursday it had signed an agreement giving Canadian-based Topigen the North American rights to develop and market its experimental NCX 1020 treatment for inflamed lungs.
